Type 2 diabetes and its effects on microRNA-155 and microRNA-133a expression in lung tissue of male rats

doi:10.21203/rs.3.rs-952437/v2

Download PDF

Research Article

Type 2 diabetes and its effects on microRNA-155 and microRNA-133a expression in lung tissue of male rats

https://doi.org/10.21203/rs.3.rs-952437/v2

This work is licensed under a CC BY 4.0 License

Version 2

posted

You are reading this latest preprint version

Backgrounds:

The presence of extensive vascular and large amounts of collagen and elastin in lung tissue makes the lung parenchyma vulnerable to damage in diabetes. However, there are few studies on the pathophysiological effects of diabetes on lung tissue. In this study, we investigated the effects of type 2 diabetes on lung tissue pathology and the expression of miRNA-155 and miRNA-133a in lung tissue of male rats.

Methods and results:

In this study, 20 male rats were divided into a control group and a group with diabetes. The diabetic group received a high-fat diet for 4 weeks. Rats were injected with a single dose of streptozotocin (STZ) after the fourth week. 4 days after STZ injection, blood glucose and glucose tolerance (GTT) tests were measured. Immediately after the tests, the mice were sacrificed and lung tissue was collected to measure microRNAs and to examine tissue changes. When lung tissue sections from diabetic rats were examined, the normal structure of the alveoli and alveolar sacs and bronchioles was disturbed. The extensive alveolar collapse was the main cause of lung tissue structure disruption, and the accumulation of inflammatory cells and exudate secretions resulted in an interstitial pneumonia-like appearance. The expression of miRNA-155 was increased, and the expression of miRNA-133a was decreased in the lungs of diabetic rats compared with control rats.

Conclusion

We found significant changes in the lung tissue of diabetic rats. By studying the changes in the expression of microRNAs in the lungs of diabetic patients, microRNA can be used as a diagnostic biomarker. These changes can provide appropriate treatment strategies.

Type 2 diabetes

lung disease

miRNA-133a

miRNA-155

Diabetes mellitus refers to several metabolic disorders, all characterized by chronic hyperglycemia. In this disease, the ability to produce the hormone insulin is lost (type 1), or the body's cells become resistant to insulin (type 2). When blood sugar levels increase and affect metabolism, complications of the disease become noticeable [1, 2]. Cardiovascular, kidney and eye complications, problems of the nervous system, disorders of peripheral organs due to nerve damage and finally, heart and ischemic stroke are complications of diabetes in the body [3]. Diabetes is the seventh most common disease in the world in terms of economic and social burden. According to the World Health Organization, more than 488 million people were diagnosed with diabetes in 2014, and more than 1.6 million deaths were directly attributable to diabetes in 2016 [4].

Lung tissue is highly prone to damage and microvascular complications in diabetes because of its large vascular extent and abundant connective tissue [5]. Decreased lung function in people with diabetes is directly related to blood glucose levels, duration of diabetes, and severity of nonsmoking disease and obesity [6].

High blood glucose levels and the duration of the disease also increase the clinical symptoms of chronic lung disease [7]. Changes in the lung tissue of patients with diabetes include 1) an increase in the thickness of the basement membrane, which is due to an inflammatory process in the lungs of a patient with diabetes. 2) neutrophil infiltration and accumulation, and an increase in alveolar wall thickness, and 3) fibrosis toward inflammatory cell infiltration, as seen in hematoxylin and eosin staining [8, 9]. The effects of diabetes on the lungs and pulmonary disease have been demonstrated in many clinical studies. However, the pathophysiology and mechanism of the effects of diabetes on pulmonary problems are still largely unknown and unclear. Previous studies have shown pathologic changes in the lung tissue of patients with diabetes, but the exact mechanism of these changes is unknown [6, 8, 10].

MicroRNAs (miRNA) are small, uncoded, protected RNAs 18–25 nucleotides in length that control gene expression after transcription by inhibiting translation or initiating degradation of mRNAs [11]. It has also been shown that each miRNA has hundreds of target genes. Thus, even if the expression of a miRNA is changed, it has a significant impact on regulating target genes [12]. Their expression may be a marker of tissue health or disease. These miRNAs can be used as potential biomarkers for diagnosis, and prognosis [13].

To date, the involvement of many miRNAs in diabetic complications such as retinopathy, nephropathy, neuropathy, and cardiovascular and pulmonary complications has been demonstrated [12, 14]. Also decrease the expression of miRNA-155 in severe asthma and its inhibition in people with lung inflammation and ductal mucus secretion. MiRNA-15 decreases the number and secretion of Th2 lymphocytes [15]. In asthma, the level of miRNA-133a decreases [16]. In asthmatic mice models increasing the expression of this miRNA decreases airway remodeling (by affecting airway smooth muscle) [17]. miRNA-133a expression is decreased in the bronchial smooth muscle of asthma patients, which increases RhoA levels and improves bronchial response and sensitivity [18]. MiR133a has a protective effect against fibrosis in human lung fibroblasts (HFL). It suppresses myofibroblast development and progression of pulmonary fibrosis by inhibiting TGF-1 [18]. It is noteworthy that quantitative proteomics research has shown that miRNA-133a suppresses myofibroblast development by targeting numerous components of the profibrogenic TGF-1 pathway. Western blot studies showed that miR-133a suppressed the production of traditional myofibroblast differentiation markers such as -smooth muscle actin (SMA), connective tissue growth factor (CTGF), and collagens in response to TGF-1 stimulation [19].

The level of miRNA-155 in the serum of patients with type 2 diabetes is low [20], suggesting that miRNA-155 controls blood glucose levels in patients with diabetes. Genetically modified mice expressing higher levels of miRNA-155 were more to have hypoglycemia and increased insulin sensitivity [21, 22]. The level of miRNA-155 in foot ulcers of study participants in the diabetes group is higher than usual [20], which suppresses FGF7, effective in wound healing and wound epithelialization. By inhibiting miRNA-155, the wound healing rate was significant [20]. Studies on the inhibition of miRNA in preclinical models of asthma, cystic fibrosis (CF), and IPF have shown that therapeutic targets are satisfactory [23–25]. In animals, microRNA inhibitors administered directly into the respiratory tract via nebulizers or inhalers increase the expression of groups of genes with complementary "seed" sequences in their mRNA-untranslated regions for selective and targeted microRNA binding. These results show that it is possible to change the way microRNAs work to develop new treatments for chronic lung diseases [26].

Glycosylated protein in the lung and thoracic tissues after hyperglycemia, the resistance of collagen to proteolysis, and finally, the accumulation of this protein in lung connective tissue may cause lung disease in patients with diabetes. Understanding the mechanism of these disorders will help diagnose and treat the lung damage caused by diabetes. MiRNAs are markers for various diseases. Therefore, in this study, we investigated the effects of type 2 diabetes on lung tissue damage and the expression of miRNA-155 and miRNA-133a in lung tissue of male rats.

Animals studied

This study was approved by the ethics committee of the Tabriz University of Medical Sciences, with code 1398/344. In this study, 20 male Wistar rats (8–10 weeks old, 180–220 g) were transferred after purchase to Animal Care Center from Tabriz University of Medical Sciences. The animals were kept in standard cages on a 12:12 dark-light cycle at temperatures ranging from 18 to 22°C, with free access to water and food. Ten days after transfection (to relieve stress and acclimate to the new environment), rats were randomly divided into two groups: Control (rats with a normal diet) and diabetic (rats with diabetes induction). The study site was the Applied-Drug Research Center of Tabriz University of Medical Sciences.

Induction of diabetes and Approval of diabetic rats

T2D was acclimatized by a HFD (22% fat, 20% protein, and 48% carbohydrate) for four weeks, followed by intraperitoneal injection of a single dose of STZ (35 mg/kg body weight) [27]. To dissolve streptozotocin (STZ), 0.1 M cold citrate buffer with a pH = 4.5 was used. Rats were randomly divided into two groups: control and diabetic: (1) control group: in this group, the animals were fed the same normal diet for five weeks, and (2) diabetic group: in this group, the animals were fed for five weeks. They received high-fat, high-protein foods plus a dose of streptozotocin (end of week 4) and were at risk for type 2 diabetes. Four days after STZ injection, type 2 diabetes developed in rats. A glucometer was used to diagnose and confirm diabetes. In this way, with a small injury by Lancet in the tail of the animal, a drop of blood was placed on the glucometer tape and the tape was then read by the glucometer and blood sugar above 250 mg/dl was considered as an indicator of diabetes. Rats in the diabetic and control groups fasted for 12 hours. A glucose tolerance test (GTT) was then performed by administering 1 g/kg glucose to the diabetic and control rats. Blood glucose levels were measured after 0, 30 min, 60 min, 90 min, and 120 min using a rat glucose meter. All measurements were performed three times by glucometer.

Preparation of lung tissue for analysis of tissue sections and expression of miRNAs

During the Fifth week after the end of the test, lung tissue was collected for the measurement of miRNAs after animals were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (10 mg/kg) to assess tissue changes. Lung tissue was washed with cold, sterile normal saline. Then, one lung was frozen to examine gene expression, and the other was fixed in 10% formalin solution to examine tissue changes. The hematoxylin-eosin (H&E) method was used to evaluate the extent of lung injury. The histopathological examination included tissue changes such as leukocyte infiltration, perivascular edema, inflammation, and pulmonary fibrosis. Histopathological changes were examined using a light microscope (Olympus CH30 made in Japan) and photographed with an Olympus DP12 camera, U-TVO.5XC-2 Japan.

MicroRNAs extraction, cDNA synthesis and real-time polymerase chain reaction

Real-time polymerase chain reaction (PCR) was used to determine the transcription of miRNA-155 and miRNA-133a. For this purpose, lung tissue was rapidly sectioned, and RNA content was extracted using TRIzol (Roche, Germany) according to the manufacturer's instructions. A Picodrop 1000 spectrophotometer (Thermo Scientific, USA) was used to determine RNA concentration and integrity. cDNA Synthesis Kit was used to generate cDNA (TaKaRa). Real-time PCR was performed on a Rotor-Gene 6000 instrument using a cocktail of cDNA sample (1L), SYBR Green Master Mix (5L; TAKARA), DEPC water (3.7L), and primers (0.3L) (Corbett, Australia). The PCR products were standardized to U6.

Statistical analysis

Analysis was performed using SPSS 19 software. All quantitative data were presented as mean ± SEM and analyzed with the student t-test. The 2ΔCt technique was used to determine the relative quantitative expression of miRNA. In this study, a value of P < 0.05 was considered significant.

GTT confirms type 2 diabetes

Before GTT measurement, the weight of diabetic rats (230–250 g) and the weight of control rats (200–220 g) were measured. Also, blood glucose of case and control groups was checked to ensure blood sugar (Fig. 1.A). GTT measurements showed that glucose tolerance was impaired in the diabetic group compared with the control group (Fig. 1.B).

The effect of diabetes on lung tissue

The lungs of both diabetic and control groups were examined by light microscopy with hematoxylin and eosin staining. The lung tissue sections of the rats in the control group showed normal tissue structure. Normal alveoli with the septum between the thin alveoli and alveolar sacs were visible. The alveoli walls were lined with type 1 and type 2 pneumocytes, each with its characteristics (type 1 pneumocytes are apartments and type II pneumocytes have large round domes) (Fig. 2.A).

When we studied the lung tissue sections of the diabetic rats, we observed the disruption of the natural structure of the alveoli and sacs and the bronchioles and interstitial vessels. The interstitial septa were thickened, mainly due to infiltration of inflammatory cells, including macrophages. We also saw an increase in the thickness of the epithelial layer covering the surface of the bronchioles. In some tissue sections, homogeneous material accumulated in the arteries, and we also noted exudative secretions between the alveoli. One of the most common findings on most slides and tissue sections was an extensive alveolar collapse, the leading cause of disruption of normal lung tissue structure. The accumulation of inflammatory cells and exudative secretions resembled interstitial pneumonia (Fig. 2.B).

The effect of diabetes on the expression of miRNA-155 and miRNA-133a in the lungs of rats

According to the results, the expression level of the miRNA-133a gene was lower in diabetic rats than in control rats (Fig. 3A) (p < 0.05). However, the expression level of the miRNA-155a gene was higher in diabetic rats than in control rats (Fig. 3B). (p < 0.01).

The prevalence of diabetes is increasing every day. Therefore, study its adverse effects, including the effects of diabetes on patients' lungs. Previous studies have demonstrated pulmonary changes in patients with diabetes [28–30]. We studied the lung tissue of rats to control the pulmonary changes in diabetes. In this study, we investigated the effects of diabetes on the expression of two genes, miRNA-155 and miRNA-133a, in the lung tissue of diabetic rats.

In a study on the effects of diabetes on lung function, two groups of diabetic and non-diabetic overweight patients were examined. According to studies, all lung capacities (FVC, FEV1, DLCO, TLC) of patients with diabetes were lower than those of non-diabetic patients [31, 32]. In a study to evaluate the histopathological changes in the lungs of diabetic rats, changes in lung tissue were investigated in two groups: the group with diabetes and the control group. It was found that a significant increase in interalveolar septa was observed after four weeks, indicating cellular infiltration.

Some bronchioles showed patchy hyperplasia of the lower epithelium. Eight weeks after the onset of diabetes, an accumulation of alveolar macrophages and inflammatory cells was observed in the lung tissue, which increased the thickness of the septum between the alveoli and caused many alveoli to collapse, disrupting the normal tissue structure. The normal tissue structure was disturbed. Obstruction and thickening of the vessels occurred with exudate of fluid and blood into the lung tissue. Collagen fiber accumulation was also increased in the group with diabetes compared with the control group [33]. In our study, the lungs of both the control and groups with diabetes were examined. We observed significant changes in the lung tissue of diabetic rats compared with the control group. Increased thickness of interalveolar septa, infiltration of inflammatory cells, exudative secretions in the interstitial space, disruption of the typical appearance of normal lung tissue due to the collapse of alveoli and bronchioles, and similar occurrence of interstitial pneumonia are the sum of our findings from the study of lung tissue sections from diabetic rats.

According to searches in databases and articles, miRNA-133a has not been studied in the lungs of patients with diabetes. Also, the role of miRNA in type 2 diabetes has rarely been discussed. This miRNA is highly expressed in cardiomyocytes. According to a study by Shali Chen et al. [34] the expression of this miRNA was decreased in diabetic rats with cardiac fibrosis.

Expression of miRNA-133a in bronchial smooth muscle is markedly reduced in asthma patients, which increase RhoA levels and enhances bronchial responsiveness and sensitivity [15]. MiRNA-133a plays an antifibrotic role in IPF by inhibiting myofibroblast differentiation and preventing lung fibrosis by inhibiting TGF-β [19]. In our study, miRNA-133a expression was lower in diabetic rats than in controls, consistent with studies in diabetes. Because miRNA-133a in the lungs of patients has been little studied, our study may represent a turning point in the study of miRNA-133a in the lungs of study participants in the diabetes group and other diseases. In our study, the expression of miRNA-155 was increased in the lungs of diabetic rats compared with control rats. A study investigating the effect of miRNA-155 on the pathogenesis of diabetes complications found that the expression of miRNA-155 was reduced in tissues other than the liver, including peripheral blood, heart, liver, sciatica, and aorta of diabetic rats. In this article, they also confirmed changes in the expression of this miRNA in diabetic rats [35]. In another study, the expression of miRNA-155 was also lower in diabetic rats [36]. However, these studies did not examine lung tissue. Thus, their results contradict our results, but they support the importance of this miRNA in diabetes.

A study by Dong Zhang et al. also showed that a deficiency of miRNA-155 plays a protective role in preventing cardiac fibrosis in diabetic rats [37]. In another study, a group concluded that miRNA-155 reduced the prophylactic effect of TGF-B [38]. In a study by Kuroska et al. [39] miRNA-155 increased collagen deposition and the production of TGF-B, which mediates pulmonary fibrosis. And Moses mentions that miRNA-155 increased collagen production mediated by TGF-B [40]. MiRNA-155 plays a vital role in the progression of systemic sclerosis. Its expression is markedly increased in the lungs of patients with systemic sclerosis, and miRNA-155 is an essential biomarker for the progression of pulmonary fibrosis in these patients. This effect could be an important target for treating this disease [41]. And high levels of this miRNA are used in the diagnosis and severity of asthma. It is directly related to IL-13 level and negatively correlates with FEC and FEV1 [42].

In non-SCC lung cancer, we have a high expression of miRNA-155, which increases disease expression [43] and is essential because one of the significant lung changes in diabetes is lung fibrosis and increased collagen production. We also obtained the same result in this study. Additionally, all these articles agree with our study in which an increase in miRNA-155 was found. Although we did not investigate the exact pathogenesis of miRNA-155 expression in diabetic lung lesions, previous studies suggest that miRNA-155 cause fibrosis and increased collagen deposition by acting on inflammatory and fibrotic factors. According to recent articles, using miRNAs as diagnostic biomarkers and therapeutic targets is strongly recommended. These miRNAs could be a good target for the treatment and, more importantly, preventing diabetic lung problems.

The prevalence of diabetes is increasing every day. Therefore, research into its side effects, including the effects of diabetes on patients' lungs, is essential. In this study, we found changes in the lung tissue of diabetic rats. We also found that the expression of miRNA-155 increased in the lungs of diabetic rats, and the expression of miRNA-133a decreased in the lungs of diabetic rats. Based on all these findings, we suggest that miRNA-155 is a significant cause of lung injury in diabetes when its expression is increased and that miRNA-133a can cause lung injury when its expression decreases. To further support these findings, we recommend conducting studies with more extensive samples and investigating changes in lung tissue by manipulating the expression of these genes to evaluate their therapeutic or prophylactic effects. During the study, we did not mention the deposition of collagen and interstitial proteins because the study of collagen deposition required Mason trichrome staining, which unfortunately was not available to our research team. We also recommend that future studies investigate the effects of diabetes on the expression of genes and miRNAs at the proteomics level.

Acknowledgments

The authors thank Tabriz University of Medical Sciences for their financial support. We also thank the staff of the Stem Cell Research Center for their cooperation and advice.

Funding

This study was supported by a grant from Tabriz University of Medical Sciences (IR.TBZMED.VCR.REC.1398.344).

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The Ethics Committee of the Tabriz University of Medical Sciences approved the study protocols following the Declaration of Helsinki.

Data availability

The data and materials used in this study are available.

Authorship contribution statement

MK: Data curation, Methodology, Writing – original draft. MA, SS, and MA: Methodology, Formal analysis. AN, RR, and BS: Conceptualization, Formal analysis, Writing – review & editing. FK: Conceptualization, Supervision, Project administration, Writing – review & editing. All authors read and approved the final manuscript.

Satisfaction with publication

All authors agree to publish the data of this study.

American Diabetes Association. (2010). Diagnosis and classification of diabetes mellitus. Diabetes care, 33(Supplement 1), pp.S62-S69. https://doi.org/
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C. and Zuñiga, F.A. (2018). Association between insulin resistance and the development of cardiovascular disease. Cardiovascular diabetology, 17(1), pp.1–14.
Chawla, A., Chawla, R. and Jaggi, S. (2016). Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?. Indian journal of endocrinology and metabolism, 20(4), p.546.
Zimmet, P., Alberti, K.G., Magliano, D.J. and Bennett, P.H. (2016). Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nature Reviews Endocrinology, 12(10), pp.616–622.
Rajasurya, V., Gunasekaran, K. and Surani, S. (2020). Interstitial lung disease and diabetes. World Journal of Diabetes, 11(8), p.351. https://doi.org/10.4239/wjd.v11.i8.351.
Klein, O.L., Krishnan, J.A., Glick, S. and Smith, L.J. (2010). Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic medicine, 27(9), pp.977–987.
Khateeb, J., Fuchs, E. and Khamaisi, M. (2019). Diabetes and lung disease: a neglected relationship. The review of diabetic studies: RDS, 15, p.1.
Ali, M.O. (2014). Pulmonary complications in diabetes mellitus. Mymensingh medical journal: MMJ, 23(3), pp.603–605.
Zheng, H., Wu, J., Jin, Z. and Yan, L.J. (2017). Potential biochemical mechanisms of lung injury in diabetes. Aging and disease, 8(1), p.7.
Bottini, P., Scionti, L., Santeusanio, F., Casucci, G. and Tantucci, C. (2000). Impairment of the respiratory system in diabetic autonomic neuropathy. Diabetes, nutrition & metabolism, 13(3), pp.165–172.
Hu, X., Wu, C., Lou, J., Ma, H., Wang, X., Xu, Y., Chen, Y., Sheng, S., Xu, H., Xu, H. and Wang, X. (2021). Potential role of microRNAs in the regulation of pyroptosis. Molecular Medicine Reports, 23(5), pp.1–9. Molecular Biology Reports, 48(8), 6085–6091.
Gunel, N. S., Birden, N., Kurt, C. C., Bagca, B. G., Shademan, B., Sogutlu, F., ... & Avci, C. B. (2021). Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer. Molecular Biology Reports, 48(8), 6085-6091.
Shademan, B., Nourazarian, A., Nikanfar, M., Avci, C.B., Hasanpour, M. and Isazadeh, A. (2020). Investigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosis. Journal of Clinical Neuroscience, 78, pp.189–193.
Fukushima, T., Taki, K., Ise, R., Horii, I. and Yoshida, T. (2011). MicroRNAs expression in the ethylene glycol monomethyl ether-induced testicular lesion. The Journal of toxicological sciences, 36(5), pp.601–611.
Chiba, Y. and Misawa, M. (2010). MicroRNAs and their therapeutic potential for human diseases: MiR-133a and bronchial smooth muscle hyperresponsiveness in asthma. Journal of pharmacological sciences, 114(3), pp.264–268.
Svitich, O. A., Sobolev, V. V., Gankovskaya, L. V., Zhigalkina, P. V., & Zverev, V. V. (2018). The role of regulatory RNAs (miRNAs) in asthma. Allergologia et Immunopathologia, 46(2), 201–205.
Shao, Y., Chong, L., Lin, P., Li, H., Zhu, L., Wu, Q. and Li, C. (2019). MicroRNA-133a alleviates airway remodeling in asthtama through PI3K/AKT/mTOR signaling pathway by targeting IGF1R. Journal of cellular physiology, 234(4), pp.4068–4080.
Chiba, Y. and Misawa, M. (2010). MicroRNAs and their therapeutic potential for human diseases: MiR-133a and bronchial smooth muscle hyperresponsiveness in asthma. Journal of pharmacological sciences, 114(3), pp.264–268.
Wei, P., Xie, Y., Abel, P.W., Huang, Y., Ma, Q., Li, L., Hao, J., Wolff, D.W., Wei, T. and Tu, Y. (2019). Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis. Cell death & disease, 10(9), pp.1–17.
Jankauskas, S. S., Gambardella, J., Sardu, C., Lombardi, A., & Santulli, G. (2021). Functional role of miR-155 in the pathogenesis of diabetes mellitus and its complications. Non-coding RNA, 7(3), 39.
Lin, X., Qin, Y., Jia, J., Lin, T., Lin, X., Chen, L., Zeng, H., Han, Y., Wu, L., Huang, S. and Wang, M. (2016). MiR-155 enhances insulin sensitivity by coordinated regulation of multiple genes in mice. PLoS genetics, 12(10), p.e1006308.
Moura, J., Sørensen, A., Leal, E.C., Svendsen, R., Carvalho, L., Willemoes, R.J., Jørgensen, P.T., Jenssen, H., Wengel, J., Dalgaard, L.T. and Carvalho, E. (2019). microRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammation. Scientific reports, 9(1), pp.1–11.
Maltby, S., Plank, M., Tay, H.L., Collison, A. and Foster, P.S. (2016). Targeting microRNA function in respiratory diseases: mini-review. Frontiers in physiology, 7, p.21.
Oglesby, I.K., Vencken, S.F., Agrawal, R., Gaughan, K., Molloy, K., Higgins, G., McNally, P., McElvaney, N.G., Mall, M.A. and Greene, C.M. (2015). miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production. European Respiratory Journal, 46(5), pp.1350–1360.
Weidner, J., Malmhäll, C. and Rådinger, M. (2019). MicroRNAs in asthma pathogenesis-from mouse to man. Journal of Translational Genetics and Genomics, 3(1).
G Karras, J., Sun, G., Tay, J. and L Jackson, A. (2013). Reflections on microRNAs in chronic pulmonary disease: looking into the miR-ror and crystal ball. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued), 12(2), pp.88–98.
Zarafshan, E., Rahbarghazi, R., Rezaie, J., Aslani, M.R., Saberianpour, S., Ahmadi, M. and Keyhanmanesh, R. (2020). Type 2 Diabetes Mellitus Provokes Rat Immune Cells Recruitment into the Pulmonary Niche by Up-regulation of Endothelial Adhesion Molecules. Advanced Pharmaceutical Bulletin.
Prentice, B.J., Jaffe, A., Hameed, S., Verge, C.F., Waters, S. and Widger, J. (2021). Cystic fibrosis-related diabetes and lung disease: an update. European Respiratory Review, 30(159).
Wang, D., Ma, Y., Tong, X., Zhang, Y. and Fan, H. (2020). Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis. Frontiers in Public Health, 8, p.196.
Lecube, A., Simó, R., Pallayova, M., Punjabi, N.M., López-Cano, C., Turino, C., Hernández, C. and Barbé, F. (2017). Pulmonary function and sleep breathing: two new targets for type 2 diabetes care. Endocrine reviews, 38(6), pp.550–573.
Fontaine-Delaruelle, C., Viart-Ferber, C., Luyton, C. and Couraud, S. (2015). Lung function in patients with diabetes mellitus. Revue de pneumologie clinique, 72(1), pp.10–16.
Rajasurya, V., Gunasekaran, K. and Surani, S. (2020). Interstitial lung disease and diabetes. World Journal of Diabetes, 11(8), p.351.
Soliman, M.E. (2010). Evaluation of Time Dependent Changes of the Rat's Lung in Experimentally Induced Diabetes Mellitus: Light and Electron Microscopic Study. Egyptian Journal of Histology, 33(1), pp.45–54.
Chen, S., Puthanveetil, P., Feng, B., Matkovich, S.J., Dorn, G.W. and Chakrabarti, S. (2014). Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. Journal of cellular and molecular medicine, 18(3), pp.415–421.
Khamaneh, A.M., Alipour, M.R., Hesari, F.S. and Soufi, F.G. (2015). A signature of microRNA-155 in the pathogenesis of diabetic complications. Journal of physiology and biochemistry, 71(2), pp.301–309.
Majid, M., Masood, A., Masoodi, S.R., Naykoo, N.A., Shah, I.A., Nissar, B., Khan, N.S., ul Afshan, F. and Ganai, B.A. (2020). Expression analysis of microRNA-155 in type 2 diabetes in Kashmiri population. International Journal of Diabetes in Developing Countries, 40(4), pp.518–524.
Zhang, D., Cui, Y., Li, B., Luo, X., Li, B. and Tang, Y. (2017). miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-β signaling pathway. Molecular BioSystems, 13(1), pp.215–224.
Chi, L., Xiao, Y., Zhu, L., Zhang, M., Xu, B., Xia, H., Jiang, Z. and Wu, W. (2019). microRNA-155 attenuates profibrotic effects of transforming growth factor-beta on human lung fibroblasts. Journal of biological regulators and homeostatic agents, 33(5), pp.1415–1424.
Kurowska-Stolarska, M., Hasoo, M.K., Welsh, D.J., Stewart, L., McIntyre, D., Morton, B.E., Johnstone, S., Miller, A.M., Asquith, D.L., Millar, N.L. and Millar, A.B. (2017). The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp.1946–1956.
Eissa, M.G. and Artlett, C.M. (2019). The microRNA miR-155 is essential in fibrosis. Non-coding RNA, 5(1), p.23.
Artlett, C.M., Sassi-Gaha, S., Hope, J.L., Feghali-Bostwick, C.A. and Katsikis, P.D. (2017). Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis research & therapy, 19(1), pp.1–8.
Karam, R.A. and Abd Elrahman, D.M. (2019). Differential expression of miR-155 and Let-7a in the plasma of childhood asthma: Potential biomarkers for diagnosis and severity. Clinical biochemistry, 68, pp.30–36.
Ren, X.Y., Han, Y.D. and Lin, Q. (2020). Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p. European review for medical and pharmacological sciences, 24(9), pp.4822–4835.

No competing interests reported.

Download PDF

Version 2

posted

You are reading this latest preprint version

Type 2 diabetes and its effects on microRNA-155 and microRNA-133a expression in lung tissue of male rats

Status:

Version 2

Abstract

Backgrounds:

Methods and results:

Conclusion

Figures

Introduction

Materials And Methods

Animals studied

Induction of diabetes and Approval of diabetic rats

Preparation of lung tissue for analysis of tissue sections and expression of miRNAs

MicroRNAs extraction, cDNA synthesis and real-time polymerase chain reaction

Statistical analysis

Results

GTT confirms type 2 diabetes

The effect of diabetes on lung tissue

Discussion

Conclusion

Declarations

References

Additional Declarations

Status:

Version 2